Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/cpt.1844 http://scihub22266oqcxt.onion/10.1002/cpt.1844 32246834!ä!32246834 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Pharmacol+Ther 2020 ; 108 (2): 242-247 Nephropedia Template TP {{tp|p=32246834|t=2020. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection |pdf=|usr=}}{{32246834}} gab.com Text Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection JO: Clin Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32246834 #FOAvip An outbreak of 2019-nCoV infection has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID-2019. In addition to the recommended antiviral drugs, such as interferon-a, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA-dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug-drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID-2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available. Twit Text FOAVip Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection ????Clin Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32246834 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32246834 #FOAvip English Wikipedia <ref>{{Cite pmid|32246834}}</ref> Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection #MMPMID32246834 Du YX; Chen XP Clin Pharmacol Ther 2020[Aug]; 108 (2): 242-247 PMID32246834show ga An outbreak of 2019-nCoV infection has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID-2019. In addition to the recommended antiviral drugs, such as interferon-a, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA-dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug-drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID-2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available. |Acetaminophen/pharmacokinetics[MESH] |Amides/administration & dosage/blood/*pharmacokinetics[MESH] |Animals[MESH] |Antiviral Agents/administration & dosage/blood/*pharmacokinetics[MESH] |COVID-19 Drug Treatment[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/drug therapy[MESH] |Drug Interactions[MESH] |Humans[MESH]Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2(epmc).pdf DeepDyve Pubget Overpricing